3-吲唑啉酮 | 5686-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-吲唑啉酮
• 英文名称: 3-indazolone
• 英文别名: Indazol-3-on；indazol-3-one；indazolone；indazolinone；3H-Indazol-3-one
• CAS: 5686-93-1
• 化学式: C₇H₄N₂O
• mdl: MFCD09880220
• 分子量: 132.122
• InChiKey: LOCAIGRSOJUCTB-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252 °C(lit.)
• 沸点：
  255.9±23.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S22
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,3-环己二烯 、 3-吲唑啉酮 以 硫酸 、 乙腈 为溶剂， 以80%的产率得到1,4,5,11b-tetrahydro-1,4-ethanopyridazo[1,2-a]indazol-6-one
  参考文献：
  名称：

  Electrosynthesis of Cyclic alpha-Carbonylazo Compounds. Chemical Stability of the Electrogenerated Dienophiles and in situ Trapping of Dienes.

  摘要：

  Dienophilic cyclic alpha-carbonylazo compounds were prepared electrochemically by oxidation of the corresponding hydrazino compounds using a flow cell fitted with a graphite felt anode in acidic methanol or acetonitrile. The instability of these compounds in methanol was first studied. In situ Diels-Alder additions of these electrogenerated dienophiles and various dienes were performed in relatively good yields in acidic methanol or acetonitrile.

  DOI：

  10.3891/acta.chem.scand.53-0807
• 作为产物：
  描述：

  3-羟基-1H-吲唑 以 甲醇 、 硫酸 为溶剂， 生成 3-吲唑啉酮
  参考文献：
  名称：

  Electrosynthesis of Cyclic alpha-Carbonylazo Compounds. Chemical Stability of the Electrogenerated Dienophiles and in situ Trapping of Dienes.

  摘要：

  Dienophilic cyclic alpha-carbonylazo compounds were prepared electrochemically by oxidation of the corresponding hydrazino compounds using a flow cell fitted with a graphite felt anode in acidic methanol or acetonitrile. The instability of these compounds in methanol was first studied. In situ Diels-Alder additions of these electrogenerated dienophiles and various dienes were performed in relatively good yields in acidic methanol or acetonitrile.

  DOI：

  10.3891/acta.chem.scand.53-0807

文献信息

• [EN] AURORA KINASE MODULATORS AND METHOD OF USE<br/>[FR] MODULATEURS D'AURORA KINASE ET PROCÉDÉ D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009117157A1

  公开（公告）日：2009-09-24

  The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式(I)的化合物，其中在此定义了A1-5和7-8，D'，L1，L2，R1，R3，R6-8，n和o，以及合成中间体，这些化合物能够调节枢纽激酶蛋白的活性，从而影响与枢纽激酶活动相关的各种疾病状态和病况。例如，这些化合物能够影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• [EN] INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSITIONS INDAZOLINONES UTILES EN TANT QU'INHIBITEURS DES KINASES
  申请人：VERTEX PHARMA

  公开号：WO2004037814A1

  公开（公告）日：2004-05-06

  The present invention provides compounds of formula (I): These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

  本发明提供了式(I)的化合物：这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK、GSK3、ERK2、CDK2、MK2、SRC、SYK和AuroRA-2的抑制剂。因此，本发明的化合物和组合物可用于治疗或减轻各种疾病的严重程度，包括但不限于心脏病、糖尿病、阿尔茨海默病、免疫缺陷病、炎症性疾病、过敏性疾病、自身免疫疾病、破坏性骨疾病如骨质疏松症、增生性疾病、传染病和病毒性疾病。
• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• [EN] INDAZOLONES AS MODULATORS OF TNF SIGNALING<br/>[FR] INDAZOLONES UTILISÉES EN TANT QUE MODULATEURS DE LA SIGNALISATION DU TNF
  申请人：ABBVIE INC

  公开号：WO2016168633A1

  公开（公告）日：2016-10-20

  The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

  该披露提供了吲唑酮化合物、药用可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该披露的化合物可能对治疗免疫和肿瘤疾病有用。
• JNK modulators
  申请人：Dunn James Patrick

  公开号：US20080146565A1

  公开（公告）日：2008-06-19

  Compounds of formula I modulate JNK: wherein the variables are as defined herein.

  式I的化合物调节JNK： 其中变量的定义如本文所述。